NCT06533358 A Clinical Study of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCI
| NCT ID | NCT06533358 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Shaanxi Micot Pharmaceutical Technology Co., Ltd. |
| Condition | Acute Coronary Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-02-27 |
| Primary Completion | 2024-12 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
An Open-label, Sequential Dose Escalation/De-escalation Clinical Trial of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCI.
Eligibility Criteria
Inclusion Criteria: 1. Male and female aged 18-85 years old (both 18 and 85 years old) 2. Diagnosis of acute coronary syndrome (ACS) 3. Subjects who will undergo PCI during hospitalization 4. Able to understand and willing to sign written informed consent prior to undertaking any study-related activities 5. Females of childbearing potential must have a negative pregnancy test result prior to enrollment or be postmenopausal for at least 1 year, or permanently sterilized for ≥ 6 weeks. For women of childbearing potential and men with female partners of childbearing potential, effective contraception must be used if they are sexually active from the time of informed consent until 90 days after MT1002 administration Exclusion Criteria: 1. cardiogenic shock, or cardiopulmonary resuscitation (CPR） 2. Suspicious aortic dissection, pericarditis, endocarditis 3. Has any history of intracranial hemorrhage or structural abnormalities 4. Transient ischemic attack, stroke within 6 months 5. History